We are live on ! Find out more
GNRX

VanEck Vectors Generic Drugs ETF
GNRX

Delisted

GNRX was delisted on the 4th of April, 2019.

Back to rankings

4 hedge funds and large institutions have $732K invested in VanEck Vectors Generic Drugs ETF in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

155% more capital invested

Capital invested by funds: $287K → $732K (+$444K)

11.41% more ownership

Funds ownership: 8.67% → 20.08% (+11%)

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$248K
2
Jane Street
Jane Street
New York
+$7.83K

Top Sellers

Rank Fund Capital Flow
1
FDCDDQ
Federation des caisses Desjardins du Quebec
Quebec, Canada
-$25.3K
2
UBS Group
UBS Group
Switzerland
-$1K

GNRX Hedge Fund Activity: Q4 2017 in Review

4 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in VanEck Vectors Generic Drugs ETF (GNRX) for Q4 2017, worth a combined $732K — up 155% from $287K a quarter earlier.

Fund positioning in GNRX was balanced in Q4 2017: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $248K. The largest seller was Federation des caisses Desjardins du Quebec, exiting entirely with an estimated $25.3K sold.

  • 4 institutional investors held VanEck Vectors Generic Drugs ETF (GNRX) as of Q4 2017, unchanged from Q3 2017.
  • Funds reported $732K of VanEck Vectors Generic Drugs ETF stock for Q4 2017, up 155% quarter-over-quarter.
  • 2 funds opened new VanEck Vectors Generic Drugs ETF positions in Q4 2017 and 2 closed out, a net change of 0 holders.
  • The largest VanEck Vectors Generic Drugs ETF buyer in Q4 2017 was Citadel Advisors, an estimated $248K added.
  • The largest VanEck Vectors Generic Drugs ETF seller in Q4 2017 was Federation des caisses Desjardins du Quebec, an estimated $25.3K sold.

Based on aggregated 13F filings for Q4 2017.